2026-05-29T13:58:29-05:00 2025-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2025-01-01 861884515 DAVOS ALZHEIMER'S COLLABORATIVE INC DAVO 7035999617 155 EAST LANCASTER AVENUE WAYNE PA 19087 GEORGE VRADENBURG CHAIR & PRESIDENT 7035999617 2026-05-29 1 RICHARD J LOCASTRO CPA P00288314 3019519090 2025 2025-03-06 01:10:19Z GEORGE VRADENBURG 155 EAST LANCASTER AVENUE WAYNE PA 19087 12470622 0 X WWW.DAVOSALZHEIMERSCOLLABORATIVE.ORG X 2020 DC SEE PART III LINE 1. 3 2 0 3 0 0 8671988 12186383 300461 60000 43530 224239 903 0 9016882 12470622 1226886 3542155 0 0 0 0 0 0 752700 9167677 12541243 10394563 16083398 -1377681 -3612776 13372417 8470178 1870549 577289 11501868 7892889 X DAC IS LEADING THE LARGEST GLOBAL RESPONSE OF ITS KIND, DRIVING SCIENTIFIC DISCOVERY AND ALIGNING HEALTH SYSTEMS TO HELP PEOPLE WORLDWIDE, INCLUDING THOSE IN LOW RESOURCED ENVIRONMENTS LEFT OUT OF PREVIOUS EFFORTS TO FIGHT ALZHEIMER'S. (SEE SCHEDULE O)WE ARE COMMITTED TO TRANSFORMING ALZHEIMER'S RESEARCH, PREVENTION AND CARE THROUGH PROVEN PRIVATE-PUBLIC MODELS, SUCH AS GAVI, CEPI AND THE GLOBAL FUND. 0 0 13167569 3538155 THE DAVOS ALZHEIMER'S COLLABORATIVE'S SYSTEM PREPAREDNESS PROGRAM AIMS TO STRENGTHEN HEALTHCARE SYSTEMS' ABILITY TO IDENTIFY AND ADDRESS ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) EARLY. KEY INITIATIVES INCLUDE THE EARLY DETECTION FELLOWSHIP, WHICH OFFERS TECHNICAL ASSISTANCE AND FUNDING TO HEALTHCARE ORGANIZATIONS (HCOS) TO IMPLEMENT THE EARLY DETECTION BLUEPRINT, FOSTERING COLLABORATION AMONG SELECTED SITES TO OVERCOME BARRIERS AND ENHANCE EARLY DETECTION. THE PROGRAM ALSO INCLUDES THE BRAIN HEALTH NAVIGATOR INITIATIVE, DESIGNED TO PILOT A BRAIN HEALTH NAVIGATOR MODEL IN SIX HCOS TO SUPPORT TIMELY CARE FOR PATIENTS WITH COGNITIVE DECLINE. ADDITIONALLY, THE ACCURATE DIAGNOSIS PROGRAM AIMS TO INCREASE THE USE OF NEW DIAGNOSTIC TOOLS, HELPING HEALTHCARE SYSTEMS ADOPT MORE EFFECTIVE METHODS FOR DIAGNOSING AD/ADRD. THESE EFFORTS ARE SUPPORTED BY SIGNIFICANT FUNDING AND ARE INTENDED TO IMPROVE SYSTEM PREPAREDNESS THROUGH OUTREACH, TRAINING, AND THE CREATION OF PRACTICAL TOOLKITS FOR HEALTHCARE PROVIDERS.OVERALL, OUTPUTS INCLUDE PEER-REVIEWED PUBLICATIONS, SYMPOSIUMS, POLICY COMMUNICATIONS, AND AN OPEN-ACCESS "BLUEPRINT" FOR AD/ADRD EARLY DETECTION AND SYSTEM PREPAREDNESS. DAC ALSO COLLABORATES WITH OTHER ORGANIZATIONS TO ADDRESS COMMON BARRIERS AND PROMOTE BEST PRACTICES ACROSS HEALTH SYSTEMS. 1667040 4000 60000 THE DAVOS ALZHEIMER'S COLLABORATIVE'S GLOBAL COHORT DEVELOPMENT PROGRAM FOCUSES ON BUILDING A DIVERSE AND SUSTAINABLE NETWORK OF COHORTS TO ADVANCE ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) RESEARCH. THIS INCLUDES PARTNERSHIPS SUCH AS THE COLLABORATION WITH AGA KHAN UNIVERSITY IN NAIROBI, KENYA, WHERE COGNITIVE TESTS, SALIVA-BASED POLYGENIC RISK SCORES, AND DIGITAL COGNITIVE ASSESSMENTS ARE BEING VALIDATED IN EAST AFRICAN POPULATIONS TO CREATE A CLINICAL TRIAL-READY COHORT. IN SOUTH KOREA, DAC HAS ACQUIRED BLOOD SAMPLES FROM 300 PARTICIPANTS IN A HIGHLY CHARACTERIZED COHORT, ADVANCING THE VALIDATION OF BLOOD-BASED BIOMARKERS (BBMS) FOR GLOBAL USE. THE PROJECT ALSO INCLUDES ACCESS TO 1,000 BLOOD SAMPLES FROM A LONG-STANDING COHORT IN THE LATAM/CARIBBEAN REGION FOR AD BLOOD BIOMARKER VALIDATION, AS WELL AS A LARGE-SCALE CLINICAL TRIAL RECRUITMENT EFFORT IN THE DOMINICAN REPUBLIC, WITH OVER 14,000 PARTICIPANTS ACROSS URBAN AND RURAL SETTINGS.FURTHER EXPANDING GLOBAL RESEARCH, DAC IS DEVELOPING SCALABLE APPROACHES IN EGYPT FOR EARLY DETECTION, MONITORING, AND RISK REDUCTION OF AD, WHILE IN INDIA, THE "EYE-DEA STUDY" IS USING CATARACT SURGERY CLINICS TO ASSESS OCULAR, SPEECH, AND OLFACTORY BIOMARKERS RELATED TO COGNITIVE IMPAIRMENT. IN CHILE, DAC IS COLLECTING A WIDE RANGE OF DATA FROM A 9,000-PERSON COHORT TO GENERATE LOCAL VALIDATION DATA FOR BLOOD BIOMARKERS AND DIGITAL COGNITIVE ASSESSMENTS, PARTICULARLY FOCUSING ON THE IMPACT OF PESTICIDE USE AND EXPOSURE TO NEUROTOXINS. THESE EFFORTS ARE HELPING TO ENSURE THAT AD RESEARCH IS INCLUSIVE OF DIVERSE POPULATIONS AND ADAPTABLE TO LOCAL SETTINGS, WITH THE AIM OF IMPROVING EARLY DETECTION, DIAGNOSIS, AND TREATMENT ON A GLOBAL SCALE. THE DAVOS ALZHEIMER'S COLLABORATIVE'S GLOBAL CLINICAL TRIAL PROGRAM IS MAINTAINING A NETWORK OF MORE THAN 30 EUROPEAN SITES ORGANIZED TO ACCELERATE STUDIES AND IMPLEMENT NOVEL TRIAL DESIGNS. THIS EFFORT IS PART OF DAC'S BROADER GOAL TO BUILD INFRASTRUCTURE FOR FUTURE PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TRIALS GLOBALLY. THROUGH THE GLOBAL COHORT DEVELOPMENT PROGRAM, DAC IS WORKING TO CREATE CLINICAL TRIAL-READY POPULATIONS BY 2026, ENSURING THAT DIVERSE AND WELL-CHARACTERIZED COHORTS ARE PREPARED FOR BOTH TYPES OF INTERVENTIONS. THIS WILL EXPAND OPPORTUNITIES FOR GLOBAL CLINICAL TRIALS, ENHANCING THE ABILITY TO TEST NEW TREATMENTS AND APPROACHES IN ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) ACROSS VARIED POPULATIONS AND SETTINGS. 14834609 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 26 0 1 0 0 1 SZ 0 0 0 0 0 0 0 0 0 0 X 3 2 0 1 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 0 0 0 X X X MIKE CLEARY 6465734430 155 EAST LANCASTER AVENUE 2ND FLOOR WAYNE PA 19087 X GEORGE VRADENBURG CHAIR & PRESIDENT 20.00 2.00 X X 0 0 0 ANDREW HOLZAPFEL COO (SEE SCHEDULE O) 30.00 3.00 X X 0 0 0 FREDA LEWIS HALL TREASURER 1.00 1.00 X X 0 0 0 0 0 0 0 0 0 0 HIGH LANTERN GROUP LLC (HLG) 685 THIRD AVENUE 22ND FLOOR NEW YORK NY 10017 ADMIN, MARKETING, PR, IT 1038887 UNIVERSITY OF KANSAS MEDICAL CENTER (KUM 3901 RAINBOW BOULEVARD MAIL STOP 10 KANSAS CITY KS 66160 PROGRAM RESEARCH FEES 650000 HAVAS HEALTH 200 MADISON AVENUE NEW YORK NY 10016 PROGRAM RESEARCH FEES 355039 WALLACE RESEARCH AND DESIGN CORP 11 BLOOMFIELD AVE TORONTO ON M4L2G2 TORONTO CA PROGRAM MANAGEMENT 318816 VAIBHAV NARAYAN 96 FLEMING WAY PRINCETON NJ 08540 PROGRAM MANAGEMENT 280657 20 12186383 4905928 12186383 CONTRACT INCOME 900099 60000 60000 60000 224239 224239 12470622 60000 0 224239 X 2323750 2323750 1218405 1218405 997537 927417 38528 31592 183815 170894 7100 5821 207171 207171 9577907 9099836 168089 309982 195886 159518 200 36168 19081 3797 15085 199 11082 2205 8763 114 1298502 918767 11430 368305 21251 4228 16804 219 BAD DEBT 25000 4974 19768 258 SUBSCRIPTION FEES 2238 445 1770 23 MISCELLANEOUS 1773 373 1381 19 16083398 14834609 496089 752700 9007029 952856 5988759 3895504 1427470 469884 101093 13372417 8470178 1870549 577289 1870549 577289 X 7659407 3998205 3842461 3894684 11501868 7892889 13372417 8470178 X -3612776 3797 X 0 1 X 1 0 X 14514120 9767900 8484685 8671988 12186383 53625076 14514120 9767900 8484685 8671988 12186383 53625076 34483925 19141151 43530 224239 267769 903 903 53893748 360461 X FORM 990, SCHEDULE A, PART II, LINE 1 THE ORGANIZATION'S EXEMPTION WAS GRANTED ON 1/12/2021 MAKING 2021 A SHORT-YEAR. THEREFORE, THE 2021 COLUMN REPRESENTS A SHORT YEAR. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 12869522 398900 398900 12470622 0 12470622 16485177 398900 2879 401779 16083398 0 16083398 PART XII, LINE 2D - OTHER ADJUSTMENTS: RELATED ORG. EXPENSES INCLUDED IN THE CONSOLIDATED 2,879. FINANCIAL STATEMENTS, BUT EXCLUDED FROM PART IX OF THE FORM 990. 1 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 230855 EUROPE 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 985550 SOUTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 2000 EAST ASIA AND THE PACIFIC 0 1 PROGRAM SERVICES SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 25000 EUROPE 0 19 PROGRAM SERVICES PROFESSIONAL FEES, RESEARCH SERVICES, MARKETING, TRAVEL LEGAL SERVICES 1696041 MIDDLE EAST AND NORTH AFRICA 0 2 PROGRAM SERVICES RESEARCH SITE AND RESEARCH SERVICES 168115 NORTH AMERICA 0 5 PROGRAM SERVICES PROGRAM SERVICES AND RESEARCH SITE 640503 SOUTH AMERICA 0 4 PROGRAM SERVICES, RESEARCH SERVICES, RESEARCH SITE AND TRAVEL RESEARCH SITE, SPONSORSHIP AND PROGRAM SERVICES 572520 SOUTH ASIA 0 2 RESEARCH SERVICES RESEARCH SITE, RESEARCH SERVICES AND TRAVEL 197782 SUB-SAHARAN AFRICA 0 10 PROGRAM SERVICES RESEARCH SERVICES, MARKETING AND TRAVEL 46060 0 31 0 12 0 43 4320584 243842 4564426 EAST ASIA & THE PACIFIC SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 230855 0 EUROPE SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 325000 0 EUROPE SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 649550 0 EUROPE SPONSORSHIP 11000 0 4 0 1 0 0 0 0 0 PART I, LINE 2: GRANTEE PROVIDES WRITTEN REPORTS AT DESIGNATED TIMES OR MILESTONES. DAC PROVIDES A SAMPLE REPORT FOR GRANTEES TO USE UNLESS OTHERWISE SPECIFIED. GRANTEES ARE REQUIRED TO PARTICIPATE IN DAC FORUMS AND PROGRAMS. GRANTEE PROVIDES DAC WITH A ROYALTY-FREE LICENSE OR OTHER PERMISSION/AUTHORIZATION NECESSARY FOR DAC TO PUBLISH INSIGHTS AND KEY FINDINGS RESULTING FROM THE PROJECT, AS SHARED WITH DAC AND THE FORUMS AND PROGRAMS (ALL IN AGGREGATE OR SUMMARY FORM). GRANTEE WILL MAINTAIN COMPLETE AND ACCURATE RECORDS OF RECEIPTS AND EXPENDITURES CHARGED AGAINST THE GRANT THAT ARE SUFFICIENTLY DETAILED TO IDENTIFY THE USE OF FUNDS IN COMPLIANCE WITH THE GRANT AGREEMENT. DAC REPRESENTATIVES REVIEW THESE RECORDS AND THE RECORDS ARE TO BE MAINTAINED FOR A MINIMUM OF 3 YEARS AFTER THE COMPLETION OF THE GRANT. 1 COMMONSPIRIT HEALTH 198 INVERNESS DRIVE WEST ENGLEWOOD CO 80112 470617373 501(C)(3) 82500 0 FELLOWSHIP DARTMOUTH -HITCHCOCK CLINIC ONE MEDICAL CENTER DRIVE LEBANON NH 03756 222715483 501(C)(3) 100000 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE EMORY UNIVERSITY 1599 CLIFTON ROAD NE - 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 82500 0 FELLOWSHIP FAMILY HEALTH CENTERS OF SOUTHERN INDIANA 1319 DUNCAN AVE JEFFERSONVILLE IN 47130 351842342 501(C)(3) 82500 0 FELLOWSHIP MEDICAL UNIVERSITY OF SOUTH CAROLINA (MUSC) 1 SOUTH PARK CIRCLE BUILDING 1 SUITE 402 CHARLESTON SC 29407 576000722 501(C)(3) 82500 0 FELLOWSHIP MEMORIAL HEALTHCARE 826 WEST KING ST OWOSSO MI 48867 381358208 501(C)(3) 100000 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE NORTON HEALTHCARE INC 224 E BROADWAY SUITE 300 LOUISVILLE KY 40202 611028725 501(C)(3) 100000 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE SCAN HEALTH PLAN 3800 KILROY AIRPORT WAY SUITE 100 LONG BEACH CA 90806 953858259 501(C)(3) 82500 0 FELLOWSHIP SHARP REES-STEAL MEDICAL GROUP INC 5651 COPELY DRIVE STE A SAN DIEGO CA 92111 956077327 501(C)(3) 100000 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND OH 44195 340714585 501(C)(3) 650000 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 501(C)(3) 165000 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE TUFTS MEDICAL CENTER 800 WASHINGTON ST 453 BOSTON MA 02111 043400617 501(C)(3) 187500 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE UMASS MEMORIAL HEALTH - HARRINGTON 365 PLANTATION STREET SUITE 301 WORCESTER MA 01605 043358566 501(C)(3) 82500 0 FELLOWSHIP UNIV OF SOUTHERN CALIFORNIA 3500 S FIGUEROA ST LOS ANGELES CA 90089 951642394 501(C)(3) 100000 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY 200 ALBERT SABIN WAY CINCINNATI OH 45267 273850988 501(C)(3) 50000 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE UNIVERSITY OF PENNSYLVANIA TRUSTEES OF 3451 WALNUT STREET5TH FLOOR FRANKLIN BUILDING PHILADELPHIA PA 191046205 231352685 501(C)(3) 82500 0 FELLOWSHIP UNIVERSITY OF WASHINGTON 4300 ROOSEVELT WAY NE SEATTLE WA 98105 916001537 115 - STATE GOVT 56250 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE USC BHN UNIVERSITY GARDENTS BLG 205 LOS ANGELES CA 90089 951642394 501(C)(3) 50000 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE VIRTUA HEALTH FOUNDATION (VHF) 303 LIPPINCOTT DR 4TH FLOOR MARLTON NJ 08053 043722352 501(C)(3) 82500 0 FELLOWSHIP 19 0 PART I, LINE 2: GRANTEE PROVIDES WRITTEN REPORTS AT DESIGNATED TIMES OR MILESTONES. DAC PROVIDES A SAMPLE REPORT FOR GRANTEES TO USE UNLESS OTHERWISE SPECIFIED. GRANTEES ARE REQUIRED TO PARTICIPATE IN DAC FORUMS AND PROGRAMS. GRANTEE PROVIDES DAC WITH A ROYALTY-FREE LICENSE OR OTHER PERMISSION/AUTHORIZATION NECESSARY FOR DAC TO PUBLISH INSIGHTS AND KEY FINDINGS RESULTING FROM THE PROJECT, AS SHARED WITH DAC AND THE FORUMS AND PROGRAMS (ALL IN AGGREGATE OR SUMMARY FORM). GRANTEE WILL MAINTAIN COMPLETE AND ACCURATE RECORDS OF RECEIPTS AND EXPENDITURES CHARGED AGAINST THE GRANT THAT ARE SUFFICIENTLY DETAILED TO IDENTIFY THE USE OF FUNDS IN COMPLIANCE WITH THE GRANT AGREEMENT. DAC REPRESENTATIVES AUDIT THESE RECORDS AND THE RECORDS ARE TO BE MAINTAINED FOR A MINIMUM OF 3 YEARS AFTER THE COMPLETION OF THE GRANT. X 12 4682475 FMV X 372 223453 FMV 0 0 0 0 PART I, COLUMN (B): THE NUMBER IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART VI, SECTION A, LINE 3 THE DAVOS ALZHEIMERS COLLABORATIVE, INC. (DAC) RETAINED AN INDEPENDENT CONTRACTOR, HIGH LANTERN GROUP, LLC (HLG), TO PROVIDE A SUITE OF MANAGEMENT SERVICES AND ADMINISTRATIVE SUPPORT, AS WELL AS THOSE DUTIES CUSTOMARILY PERFORMED BY AN ORG. CHAIR/PRESIDENT AND COO. DAC COMPENSATED HLG $1,038,887 FOR THOSE SERVICES. THE DUTIES OF THE CHAIR/PRESIDENT AND COO WERE PROVIDED TO DAC BY GEORGE VRADENBURG AND ANDREW HOLZAPFEL, RESPECTIVELY. OF THE $1,038,887 COMPENSATION PAID TO HLG BY DAC, $70,000 IS RELATED TO THE SERVICES PROVIDED BY ANDREW HOLZAPFEL. GEORGE VRADENBURG DOES NOT RECEIVE ANY SALARY OR PAYMENT. FORM 990, PART VI, SECTION A, LINE 8B THE ORGANIZATION HAS NO COMMITTEE WITH THE AUTHORITY TO ACT ON BEHALF OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY THE OUTSIDE ACCOUNTANTS. THE 990 WAS THEN REVIEWED WITH DAC'S COO AND CHAIR/PRESIDENT WITH THE AUDITORS. IT WAS THEN SHARED WITH THE BOARD AND FINALIZED UPON APPROVAL. FORM 990, PART VI, SECTION B, LINE 12C ALL OFFICERS, DIRECTORS OR TRUSTEES AND KEY EMPLOYEES(CONTRACTORS) ARE REQUIRED TO SIGN THE CONFLICT OF INTEREST POLICY AT THE FIRST BOARD MEETING OF THE YEAR AND UPON CONTRACTING OR DATE OF HIRE. IF A CONFLICT OF INTEREST IS FOUND, THE MATTER IS PRESENTED TO THE BOARD. THE APPLICABLE INTERESTED PERSON MAKES A PRESENTATION AT THE BOARD MEETING, BUT AFTER THE PRESENTATION, HE OR SHE REFRAINS FROM VOTING OR OTHERWISE ATTEMPTING TO EXERT ANY INFLUENCE ON WHETHER THE CORPORATION SHOULD PARTICIPATE OR NOT PARTICIPATE IN SUCH TRANSACTION AND LEAVES THE MEETING DURING THE DISCUSSION OF, AND VOTE ON, THE TRANSACTION OR ARRANGEMENT INVOLVING THE POSSIBLE CONFLICT OF INTEREST. AFTER EXERCISING DUE DILIGENCE, THE BOARD DETERMINES WHETHER THE CORPORATION CAN OBTAIN WITH REASONABLE EFFORTS A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY POSSIBLE UNDER CIRCUMSTANCES NOT PRODUCING A CONFLICT OF INTEREST, THE BOARD DETERMINES BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN THE CORPORATION'S BEST INTEREST, WHETHER IT IS FAIR, REASONABLE, AND THE RESULT OF ARM'S-LENGTH BARGAINING, AND WHETHER IT REFLECTS REASONABLE INVESTMENT CRITERIA OR PAYMENTS FOR GOODS AND SERVICES, FURTHERS THE CORPORATION'S PURPOSES AND DOES NOT RESULT IN PRIVATE INUREMENT, IMPERMISSIBLE PRIVATE BENEFIT OR AN EXCESS BENEFIT TRANSACTION. IN CONFORMITY WITH THE ABOVE DETERMINATION, THE BOARD OR COMMITTEE MAKES ITS DECISION IN WRITING AND ON THE RECORD AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G CONTRIBUTED TESTING EXPENSES: PROGRAM SERVICE EXPENSES 4,284,682. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 4,284,682. FUNDRAISING SERVICES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 295,071. TOTAL EXPENSES 295,071. PROGRAM OPERATIONS SERVICES: PROGRAM SERVICE EXPENSES 1,820,228. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,820,228. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 466,907. MANAGEMENT AND GENERAL EXPENSES 168,089. FUNDRAISING EXPENSES 14,911. TOTAL EXPENSES 649,907. RESEARCH FEES: PROGRAM SERVICE EXPENSES 2,528,019. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,528,019. FORM 990, PART XI, LINE 9: CURRENCY EXCHANGE LOSS 3,797. DAVOS ALZHEIMER'S COLLABORATIVE (GENEVE) COURS DE RIVE 13 C/O PESTALOZZI AV GENEVE SZ 1204 PROMOTE HEALTH BY DEVELOPING RESEARCH ON BRAIN HEALTH.. SZ N/A N/A DAC 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 DAVOS ALZHEIMER'S COLLABORATIVE (GENEVE) Q 2778 ACTUAL COST